{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:38:05Z","timestamp":1788824285146,"version":"build-2803163510"},"reference-count":93,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005039","name":"Leids Universitair Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012324","name":"University Hospitals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","award":["2014-083"],"award-info":[{"award-number":["2014-083"]}],"id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","award":["2019-091"],"award-info":[{"award-number":["2019-091"]}],"id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.bneo.2024.100023","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T21:42:04Z","timestamp":1718228524000},"page":"100023","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9793-7032","authenticated-orcid":false,"given":"Paul G.","family":"Kemps","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7840-6156","authenticated-orcid":false,"given":"F. J. Sherida H.","family":"Woei-A-Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-030X","authenticated-orcid":false,"given":"Patrick","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0397-1086","authenticated-orcid":false,"given":"Thomas","family":"Tousseyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3433-555X","authenticated-orcid":false,"given":"Isabelle","family":"Vanden Bempt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6277-1973","authenticated-orcid":false,"given":"Friederike A. G.","family":"Meyer-Wentrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasja","family":"Dors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0526-3737","authenticated-orcid":false,"given":"Natasha K. A.","family":"van Eijkelenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-1140","authenticated-orcid":false,"given":"Marijn A.","family":"Scheijde-Vermeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4264-7972","authenticated-orcid":false,"given":"Ingrid M.","family":"Jazet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4859-3250","authenticated-orcid":false,"given":"Maarten","family":"Limper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8092-3566","authenticated-orcid":false,"given":"Margot","family":"Jak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1437-214X","authenticated-orcid":false,"given":"Robert M.","family":"Verdijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7336-3262","authenticated-orcid":false,"given":"Marjolein L.","family":"Donker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9901-0887","authenticated-orcid":false,"given":"Nick A.","family":"de Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7907-7390","authenticated-orcid":false,"given":"Carel J. M.","family":"van Noesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4181-3302","authenticated-orcid":false,"given":"Konnie M.","family":"Hebeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9742-674X","authenticated-orcid":false,"given":"Suzanne","family":"van Dorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3253-8759","authenticated-orcid":false,"given":"Sanne H.","family":"Tonino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8885-4929","authenticated-orcid":false,"given":"Jan A. M.","family":"van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6175-6077","authenticated-orcid":false,"given":"Cor","family":"van den Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0563-4155","authenticated-orcid":false,"given":"Astrid G. S.","family":"van Halteren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Beckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merlijn","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cor","family":"van den Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godelieve","family":"de Bree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmeline","family":"Buddingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristl","family":"Claeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"van Daele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"De Haes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Demandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"van Dorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth","family":"Hak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"van Halteren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"van der Houwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Jak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Kerstens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan","family":"Kwakernaak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Leavis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roos","family":"Leguit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan","family":"van de Loosdrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linde","family":"Morsink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogier","family":"Mous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"van Noesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimke","family":"Oostvogels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Potjewijd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Plattel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Roeloffzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Rutgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"Tonino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Tousseyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Verdijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Vermaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherida","family":"Woei-A-Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.bneo.2024.100023_bib1","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","volume":"127","author":"Emile","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2024.100023_bib2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bneo.2024.100023_bib3","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2024.100023_bib4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/his.15127","article-title":"Demographics and additional haematologic cancers of patients with histiocytic\/dendritic cell neoplasms","volume":"84","author":"Kemps","year":"2024","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.bneo.2024.100023_bib5","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/bjh.18459","article-title":"Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: a national registry study from England, 2013-2019","volume":"199","author":"Liu","year":"2022","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.bneo.2024.100023_bib6","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","article-title":"Recurrent BRAF mutations in Langerhans cell histiocytosis","volume":"116","author":"Badalian-Very","year":"2010","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.bneo.2024.100023_bib7","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2012-05-430140","article-title":"High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses","volume":"120","author":"Haroche","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2024.100023_bib8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/his.12416","article-title":"Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms","volume":"65","author":"Go","year":"2014","journal-title":"Histopathology"},{"issue":"20","key":"10.1016\/j.bneo.2024.100023_bib9","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1182\/blood-2013-06-511139","article-title":"Somatic activating ARAF mutations in Langerhans cell histiocytosis","volume":"123","author":"Nelson","year":"2014","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.bneo.2024.100023_bib10","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2014-05-577825","article-title":"Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis","volume":"124","author":"Chakraborty","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bneo.2024.100023_bib11","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood-2014-05-577361","article-title":"High prevalence of somatic MAP2K1 mutations in BRAF V600E negative Langerhans cell histiocytosis","volume":"124","author":"Brown","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2024.100023_bib12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/gcc.22247","article-title":"MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis","volume":"54","author":"Nelson","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"issue":"21","key":"10.1016\/j.bneo.2024.100023_bib13","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood-2016-08-733790","article-title":"Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis","volume":"128","author":"Chakraborty","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2024.100023_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12943-017-0690-z","article-title":"New somatic BRAF splicing mutation in Langerhans cell histiocytosis","volume":"16","author":"H\u00e9ritier","year":"2017","journal-title":"Mol Cancer"},{"issue":"2","key":"10.1016\/j.bneo.2024.100023_bib15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2159-8290.CD-15-0913","article-title":"Diverse and targetable kinase alterations drive histiocytic neoplasms","volume":"6","author":"Diamond","year":"2016","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.bneo.2024.100023_bib16","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-019-0653-6","article-title":"Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms","volume":"25","author":"Durham","year":"2019","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.bneo.2024.100023_bib17","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/bloodadvances.2022007947","article-title":"Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study","volume":"7","author":"Kemps","year":"2023","journal-title":"Blood Adv"},{"issue":"7749","key":"10.1016\/j.bneo.2024.100023_bib18","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","article-title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","volume":"567","author":"Diamond","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bneo.2024.100023_bib19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-8-72","article-title":"Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net","volume":"8","author":"Girschikofsky","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"17","key":"10.1016\/j.bneo.2024.100023_bib20","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1182\/blood.2021014343","article-title":"International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults","volume":"139","author":"Goyal","year":"2022","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.bneo.2024.100023_bib21","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/blood.2019003507","article-title":"Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era","volume":"135","author":"Goyal","year":"2020","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.bneo.2024.100023_bib22","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1182\/blood-2018-03-839753","article-title":"Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease","volume":"131","author":"Abla","year":"2018","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.bneo.2024.100023_bib23","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1182\/blood-2012-09-455774","article-title":"Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis","volume":"121","author":"Gadner","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2024.100023_bib24","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/bloodadvances.2016001784","article-title":"The clinical spectrum of Erdheim-Chester disease: an observational cohort study","volume":"1","author":"Estrada-Veras","year":"2017","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.bneo.2024.100023_bib25","doi-asserted-by":"crossref","first-page":"E114","DOI":"10.1002\/ajh.25055","article-title":"Phenotypes and survival in Erdheim-Chester disease: results from a 165-patient cohort","volume":"93","author":"Cohen-Aubart","year":"2018","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.bneo.2024.100023_bib26","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/neuonc\/noaa008","article-title":"Neurologic and oncologic features of Erdheim\u2013Chester disease: a 30-patient series","volume":"22","author":"Bhatia","year":"2020","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2024.100023_bib27","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3324\/haematol.2019.219626","article-title":"Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease","volume":"105","author":"Goyal","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.bneo.2024.100023_bib28","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/pbc.22326","article-title":"Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine\/cytosine arabinoside","volume":"54","author":"Allen","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.bneo.2024.100023_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26784","article-title":"Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: current views and new vistas","volume":"65","author":"Yeh","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.bneo.2024.100023_bib30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2017-10-812495","article-title":"Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes","volume":"131","author":"Kommalapati","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bneo.2024.100023_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100268","article-title":"Malignant histiocytosis comprises a phenotypic spectrum that parallels the lineage differentiation of monocytes, macrophages, dendritic cells, and Langerhans cells","volume":"36","author":"Ravindran","year":"2023","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.bneo.2024.100023_bib32","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1093\/neuonc\/noab107","article-title":"Histiocytosis and the nervous system: from diagnosis to targeted therapies","volume":"23","author":"Cohen Aubart","year":"2021","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2024.100023_bib33","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3324\/haematol.11827","article-title":"Neurodegenerative central nervous system disease as late sequelae of Langerhans cell histiocytosis. report from the Japan LCH Study Group","volume":"93","author":"Imashuku","year":"2008","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.bneo.2024.100023_bib34","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/bjh.15577","article-title":"Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study","volume":"183","author":"H\u00e9ritier","year":"2018","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.bneo.2024.100023_bib35","first-page":"1537","article-title":"The cognitive spectrum in neurodegenerative Langerhans cell histiocytosis","volume":"261","author":"Le Guennec","year":"2014","journal-title":"J\u00a0Neurol"},{"issue":"6","key":"10.1016\/j.bneo.2024.100023_bib36","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3174\/ajnr.A0509","article-title":"Long-term MR imaging course of neurodegenerative Langerhans cell histiocytosis","volume":"28","author":"Prosch","year":"2007","journal-title":"AJNR Am J Neuroradiol"},{"issue":"4","key":"10.1016\/j.bneo.2024.100023_bib37","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/brain\/awh403","article-title":"Neuropathology of CNS disease in Langerhans cell histiocytosis","volume":"128","author":"Grois","year":"2005","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.bneo.2024.100023_bib38","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jpeds.2010.03.001","article-title":"Central nervous system disease in Langerhans cell histiocytosis","volume":"156","author":"Grois","year":"2010","journal-title":"J\u00a0Pediatr"},{"issue":"12","key":"10.1016\/j.bneo.2024.100023_bib39","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/cncr.31348","article-title":"CNS Langerhans cell histiocytosis: common hematopoietic origin for LCH-associated neurodegeneration and mass lesions","volume":"124","author":"McClain","year":"2018","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.bneo.2024.100023_bib40","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/j.immuni.2023.11.011","article-title":"Circulating senescent myeloid cells infiltrate the brain and cause neurodegeneration in histiocytic disorders","volume":"56","author":"Wilk","year":"2023","journal-title":"Immunity"},{"issue":"7015","key":"10.1016\/j.bneo.2024.100023_bib41","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nature03095","article-title":"Targeted cancer therapy","volume":"432","author":"Sawyers","year":"2004","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.bneo.2024.100023_bib42","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2012-07-446286","article-title":"Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation","volume":"121","author":"Haroche","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2024.100023_bib43","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/jamaoncol.2015.0736","article-title":"Vemurafenib use in an infant for high-risk Langerhans cell histiocytosis","volume":"1","author":"H\u00e9ritier","year":"2015","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.bneo.2024.100023_bib44","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.bneo.2024.100023_bib45","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/JCO.2014.57.1950","article-title":"Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF V600E -mutated Erdheim-Chester disease","volume":"33","author":"Haroche","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.bneo.2024.100023_bib46","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1182\/bloodadvances.2016003533","article-title":"Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH","volume":"1","author":"Kolenov\u00e1","year":"2017","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.bneo.2024.100023_bib47","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","article-title":"Vemurafenib for BRAF V600\u2013mutant Erdheim-Chester disease and Langerhans cell histiocytosis","volume":"4","author":"Diamond","year":"2018","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.bneo.2024.100023_bib48","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1038\/jid.2011.147","article-title":"Mechanisms of resistance to RAF inhibitors in melanoma","volume":"131","author":"Aplin","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"issue":"4","key":"10.1016\/j.bneo.2024.100023_bib49","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.3324\/haematol.2017.185298","article-title":"Single-agent dabrafenib for BRAFV600E-mutated histiocytosis","volume":"103","author":"Bhatia","year":"2018","journal-title":"Haematologica"},{"issue":"24","key":"10.1016\/j.bneo.2024.100023_bib50","doi-asserted-by":"crossref","first-page":"7294","DOI":"10.1158\/1078-0432.CCR-17-3572","article-title":"A\u00a0phase I and pharmacokinetic study of oral dabrafenib in children and adolescent patients with recurrent or refractory BRAF V600 mutation-positive solid tumors","volume":"25","author":"Kieran","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.bneo.2024.100023_bib51","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/bloodadvances.2022008414","article-title":"Dabrafenib, alone or in combination with trametinib, in BRAF V600\u2013mutated pediatric Langerhans cell histiocytosis","volume":"7","author":"Whitlock","year":"2023","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.bneo.2024.100023_bib52","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1056\/NEJMc1713676","article-title":"Rosai\u2013Dorfman disease with activating KRAS mutation \u2014 response to cobimetinib","volume":"377","author":"Jacobsen","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.bneo.2024.100023_bib53","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMc1511490","article-title":"Trametinib in histiocytic sarcoma with an activating MAP2K1 (MEK1) mutation","volume":"378","author":"Gounder","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.bneo.2024.100023_bib54","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/bjh.14284","article-title":"Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease","volume":"180","author":"Cohen Aubart","year":"2018","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.bneo.2024.100023_bib55","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1001\/jamaoncol.2022.4432","article-title":"Outcomes after treatment with cobimetinib in patients with Rosai-Dorfman disease based on KRAS and MEK alteration status","volume":"8","author":"Abeykoon","year":"2022","journal-title":"JAMA Oncol"},{"issue":"15","key":"10.1016\/j.bneo.2024.100023_bib56","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1182\/bloodadvances.2022009013","article-title":"Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis","volume":"7","author":"Aaroe","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.bneo.2024.100023_bib57","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1634\/theoncologist.2018-0295","article-title":"FDA approval summary: vemurafenib for the treatment of patients with Erdheim-Chester disease with the BRAFV600 mutation","volume":"23","author":"Oneal","year":"2018","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.bneo.2024.100023_bib58","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood.2021013338","article-title":"ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition","volume":"139","author":"Kemps","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2024.100023_bib61","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/2159-8290.CD-17-1452","article-title":"Allele-specific mechanisms of activation of MEK1 mutants determine their properties","volume":"8","author":"Gao","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bneo.2024.100023_bib59","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jdcr.2023.03.024","article-title":"Vulvar Langerhans cell histiocytosis: clinicopathologic characteristics, mutational profile, and treatment of 4 patients in a single-center cohort","volume":"36","author":"Renier","year":"2023","journal-title":"JAAD Case Rep"},{"issue":"13","key":"10.1016\/j.bneo.2024.100023_bib60","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/blood.2023020569","article-title":"Childhood-onset Erdheim-Chester disease in the molecular era: clinical phenotypes and long-term outcomes of 21 patients","volume":"142","author":"Pegoraro","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2024.100023_bib62","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0022-510X(96)00231-6","article-title":"International cooperative ataxia rating scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology","volume":"145","author":"Trouillas","year":"1997","journal-title":"J\u00a0Neurol Sci"},{"issue":"11","key":"10.1016\/j.bneo.2024.100023_bib63","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2017-03-771873","article-title":"Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)","volume":"130","author":"Cohen Aubart","year":"2017","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.bneo.2024.100023_bib64","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.19.00456","article-title":"Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study","volume":"37","author":"Donadieu","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.bneo.2024.100023_bib65","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2018-10-878363","article-title":"Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition","volume":"133","author":"Eckstein","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2024.100023_bib66","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4143\/crt.2020.769","article-title":"Effectiveness and safety of dabrafenib in the treatment of 20 Chinese children with BRAFV600E-mutated Langerhans cell histiocytosis","volume":"53","author":"Yang","year":"2021","journal-title":"Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.bneo.2024.100023_bib67","first-page":"1137","article-title":"Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders","volume":"109","author":"Cournoyer","year":"2024","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.bneo.2024.100023_bib68","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/pbc.22810","article-title":"Pediatric histiocytic sarcoma clonally related to precursor B-cell acute lymphoblastic leukemia with homozygous deletion of CDKN2A encoding p16INK4A","volume":"56","author":"Kumar","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.bneo.2024.100023_bib69","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00428-022-03428-y","article-title":"PAX5 P80R-mutated B-cell acute lymphoblastic leukemia with transformation to histiocytic sarcoma: clonal evolution assessment using NGS-based immunoglobulin clonality and mutation analysis","volume":"483","author":"Kroeze","year":"2023","journal-title":"Virchows Arch"},{"issue":"8","key":"10.1016\/j.bneo.2024.100023_bib70","doi-asserted-by":"crossref","first-page":"E216","DOI":"10.1002\/ajh.26983","article-title":"Transdifferentiation of B-lymphoblastic leukemia to histiocytic sarcoma after immunotherapy","volume":"98","author":"Fenu","year":"2023","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.bneo.2024.100023_bib71","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1634\/theoncologist.2019-0606","article-title":"Real-world toxicity experience with BRAF\/MEK inhibitors in patients with Erdheim-Chester disease","volume":"25","author":"Saunders","year":"2020","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.bneo.2024.100023_bib72","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1080\/10428194.2020.1783447","article-title":"Low-dose vemurafenib monotherapy in BRAF V600E -mutated Erdheim-Chester disease","volume":"61","author":"Ruan","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.bneo.2024.100023_bib73","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bjh.18964","article-title":"Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms","volume":"203","author":"Reiner","year":"2023","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.bneo.2024.100023_bib74","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/bloodadvances.2021005442","article-title":"Vemurafenib acts as a molecular on-off switch governing systemic inflammation in Langerhans cell histiocytosis","volume":"6","author":"Eder","year":"2022","journal-title":"Blood Adv"},{"issue":"18","key":"10.1016\/j.bneo.2024.100023_bib75","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/bloodadvances.2022009067","article-title":"Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E\u2013positive LCH","volume":"7","author":"Evseev","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bneo.2024.100023_bib76","doi-asserted-by":"crossref","DOI":"10.1093\/noajnl\/vdaa024","article-title":"Dual BRAF\/MEK blockade restores CNS responses in BRAF-mutant Erdheim\u2013Chester disease patients following BRAF inhibitor monotherapy","volume":"2","author":"Mazor","year":"2020","journal-title":"Neuro-Oncology Adv"},{"issue":"6","key":"10.1016\/j.bneo.2024.100023_bib77","article-title":"A\u00a0brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas","volume":"19","author":"Sun","year":"2017","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2024.100023_bib78","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","article-title":"The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial","volume":"30","author":"Kilburn","year":"2024","journal-title":"Nat Med"},{"issue":"S7","key":"10.1016\/j.bneo.2024.100023_bib79","first-page":"S8","article-title":"Children with refractory histiocytosis treated by MAPKi have a high risk of neurodegeneration: an international study","volume":"70","author":"Donadieu","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"10.1016\/j.bneo.2024.100023_bib80","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrd3847","article-title":"Vemurafenib: the first drug approved for BRAF-mutant cancer","volume":"11","author":"Bollag","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1016\/j.bneo.2024.100023_bib81","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.bneo.2024.100023_bib82","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1182\/bloodadvances.2022007519","article-title":"Cellular distribution of mutations and association with disease risk in Langerhans cell histiocytosis without BRAF V600E","volume":"6","author":"Milne","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.bneo.2024.100023_bib83","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1182\/bloodadvances.2021006732","article-title":"Lineage switching of the cellular distribution of BRAFV600E in multisystem Langerhans cell histiocytosis","volume":"7","author":"Milne","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.bneo.2024.100023_bib84","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1084\/jem.20130977","article-title":"BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups","volume":"211","author":"Berres","year":"2014","journal-title":"J\u00a0Exp Med"},{"issue":"3","key":"10.1016\/j.bneo.2024.100023_bib85","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.14695","article-title":"Circulating cell-free BRAF V600E as a biomarker in children with Langerhans cell histiocytosis","volume":"178","author":"H\u00e9ritier","year":"2017","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.bneo.2024.100023_bib86","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2016-12-757823","article-title":"Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults","volume":"130","author":"Milne","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2024.100023_bib87","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/s41390-018-0238-y","article-title":"Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis","volume":"85","author":"Schwentner","year":"2019","journal-title":"Pediatr Res"},{"issue":"19","key":"10.1016\/j.bneo.2024.100023_bib88","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.2020005209","article-title":"Bone marrow\u2013derived myeloid progenitors as driver mutation carriers in high- and low-risk Langerhans cell histiocytosis","volume":"136","author":"Xiao","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bneo.2024.100023_bib89","doi-asserted-by":"crossref","first-page":"e444","DOI":"10.3324\/haematol.2019.229187","article-title":"Circulating cell-free BRAF V600E during chemotherapy is associated with prognosis of children with Langerhans cell histiocytosis","volume":"105","author":"Cui","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.bneo.2024.100023_bib90","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjh.17721","article-title":"A\u00a0circulating subset of BRAF V600E -positive cells in infants with high-risk Langerhans cell histiocytosis treated with BRAF inhibitors","volume":"194","author":"Poch","year":"2021","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.bneo.2024.100023_bib91","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1158\/1535-7163.MCT-20-1075","article-title":"BRAF V600E mutation in cell-free DNA, rather than in lesion tissues, at diagnosis is an independent prognostic factor in children with Langerhans cell histiocytosis","volume":"20","author":"Wang","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.bneo.2024.100023_bib92","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/bjh.18247","article-title":"Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma","volume":"198","author":"Sveijer","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.bneo.2024.100023_bib93","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/bjh.17781","article-title":"Response to mitogen-activated protein kinase inhibition of neurodegeneration in Langerhans cell histiocytosis monitored by cerebrospinal fluid neurofilament light as a biomarker: a pilot study","volume":"196","author":"Henter","year":"2022","journal-title":"Br J Haematol"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T02:57:17Z","timestamp":1762657037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328024000232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":93,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2950328024000232"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100023","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society of Hematology.","name":"copyright","label":"Copyright"}],"article-number":"100023"}}